Vastarel MR 35 mg

Add-on therapy for the symptomatic treatment of stable angina pectoris in adults who are not adequately controlled by, or cannot tolerate, first-line anti-anginal drugs.

Trimetazidine inhibits fatty acid oxidation in heart muscle cells and shifts energy production towards glucose oxidation, which needs less oxygen. It protects the ischaemic heart muscle without changing heart rate or blood pressure.

Modified release tablet 35 mg: one tablet twice daily, morning and evening, with meals. Moderate renal impairment: 35 mg once daily in the morning. Use with caution in the elderly.

Dizziness, headache, abdominal pain, diarrhoea, indigestion, nausea, rash and weakness. Tremor, stiffness and other parkinsonian symptoms are rare.

Not for relief of an acute angina attack. Stop the drug if movement disorders such as tremor or unsteady walking appear. Avoid in pregnancy and breast-feeding.

Parkinson's disease, parkinsonian symptoms, tremor, restless leg syndrome and other movement disorders, severe renal impairment and hypersensitivity to trimetazidine.

Store below 30°C in a cool, dry place, away from light. Keep out of the reach of children.